This issue describes Russian commercial pharmacy market in February 2007.
Russian Pharmaceutical Market. April 2007 ( *.pdf file 578.5 Kb )
SUMMARY:
Drugs commercial market value in pharmacy purchase prices increased by 12.5% in February compared to January 2007 and amounted to 435 mln dollars (VAT included), which is 22% higher than in February 2006.
The weighted average price per drug unit on Russian commercial market slightly increased and amounted to 39 rubles ($1.48) in February 2007.
According to Laspeyres index prices almost did not change in comparison to January 2007: they decreased by 0.1% in rubles and increased by 0.6% in dollars.
Drugs consumption structure was almost the same in February 2007 as in January 2007. The highest increase was observed for the drugs segment priced at 50–150 rubles per unit (market share 37.6%). The average unit price in February 2007 was at the level of January 2007 for all price segments.
In February 2007, domestic drugs market share increased by 2% in value terms compared to January 2007 and amounted to 26% of commercial market.
Rx drugs market share decreased by 2% in February 2007 and amounted to 55% of total market value.
An incredible growth of Pharmstandard company (+48.5% to January 2007) became the event of month: it became the first among all pharmaceutical companies in February 2007 by sales value. Sanofi-Aventis and Berlin-Chemie /A.Menarini/ are the 2nd and the 3rd ones despite of their sales decrease.
Arbidol (2.07% market share) leads the TOP drug trade names by pharmacy sales value in Russia for February 2007, Theraflu (1.13%) is on the second place and Anaferon (0.82%) is on the third place.
In February 2007 Russian NS (nutritional supplements) pharmacy market value increased by 16% compared to January 2007 and amounted to $27.4 mln, as well as it increased by 4.3% compared to that of February 2006. Russian NS pharmacy market volume increased by 14.4% in February 2007 compared to January 2007 and amounted to 16 mln units.
The weighted average cost per NS unit amounted to $1.71 in February 2007.
All market reviews by DSM Group are available on the page Analytics.
